Clinical trials of immunotherapy with anti-programmed cell death 1 antibodies also did not meet clinical survival endpoints in patients with GBM (Khasraw et al., 2020; Maghrouni et al., 2021). This evidence concerns the gene PDCD1 and glioblastoma.